Glenmark Pharmaceuticals Launches New Constipation Treatment in the US

Glenmark Pharmaceuticals has introduced a new constipation treatment, polyethylene glycol 3350 powder, to the US market. This launch aims to fulfill the rising demand for a fresh supplier in the constipation treatment category, comparable to the active ingredient in MiraLAX. The OTC market for this product achieved annual sales of $555.7 million.

Glenmark Pharmaceuticals has introduced a new solution to address constipation with the launch of polyethylene glycol 3350 powder in the US market. The over-the-counter (OTC) medicine, similar in strength to MiraLAX's 17 grams per capful treatment, marks a significant addition to available constipation treatments.

The company, through Glenmark Therapeutics Inc., USA, aims to meet the increasing demand for this type of product by bringing a new supplier into the segment, as confirmed by Marc Kikuchi, Glenmark President & Business Head for North America.

According to Nielsen data for the latest 52-week period ending February 22, 2025, the MiraLAX powder market achieved annual sales of approximately USD 555.7 million, underscoring the strong demand for effective OTC constipation treatments. Glenmark's latest launch reaffirms its commitment to providing high-quality, accessible healthcare solutions.

(With inputs from agencies.)